Article Text

Download PDFPDF
The unintended consequences of NICE

Statistics from Altmetric.com

Footnotes

  • Contributors I have personally written this commentary.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests In the last 5 years Professor GG has received compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Actelion, Atara Bio, Biogen, Celgene, Genzyme-Sanofi, Genentech, GSK, Merck-Serono, Novartis, Roche, Synthon BV and Teva.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles